<qa>  What is the safety endpoint for the evaluation of the nature and frequency of Adverse Events?2. To assess the safety and feasibility of using the transendocardial injection catheter MyoCathTM as a system for delivering MyoCellTM into myocardial scar tissue of subjects with congestive heart failure who have experienced previous myocardial infarctions and have an implantable cardioverter defibrillator ICD previously implanted. Catheter performance will be assessed at the time of the implantation using clinical evaluation questionnaires. Safety endpoints will be the evaluation of the nature and frequency of Adverse Events from the time of implantation to the Day 14 follow-up visit. 